Frankfurt, July 7, 2022 – McDermott Will & Emery advised Ryvu Therapeutics S.A. on entering into an exclusive license agreement with Exelixis. The cooperation is focused on the development of novel targeted therapies utilizing Ryvu’s STING (STimulator of INterferon Genes) technology.

Under the terms of the agreement, Exelixis will pay Ryvu an upfront fee of $3 million in exchange for certain rights to Ryvu’s STING agonist small molecules, which Exelixis will seek to incorporate into targeted therapies such as ADCs. Ryvu will provide expert guidance and know-how during the early research phase of the partnership, and will be eligible to receive development, regulatory and commercialization milestone payments, as well as tiered royalties on the annual net sales of any products that are successfully commercialized under the collaboration.

Ryvu Therapeutics S.A. is a clinical-stage drug discovery and development company focused on novel small molecule therapies that address emerging targets in oncology. The company headquartered in Krakow, Poland, is listed on the Warsaw Stock Exchange.

Founded in 1994, Exelixis, Inc. is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers.

Ryvu Therapeutics S.A. was advised by Frankfurt Counsel Monika Emilia Richter.

McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices, industries and more than 20 locations to deliver highly effective—and often unexpected—solutions that propel success. More than 1,200 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.